Cost pressure of the new hepatitis C drugs in Canada: H82-25/2016-PDF
Pressions exercées sur les coûts des nouveaux médicaments contre l’hépatite C au Canada.
"The pricing, utilization and cost related to the direct-acting antivirals (DAAs) for the treatment of hepatitis C has become a critical issue for public plans, private insurers and patients. This study provides insight into the use, pricing and cost of DAAs in Canada and internationally in 2015, along with a retrospective look at the recent trends. The international analysis focuses on the PMPRB7 countries: France, Germany, Italy, Sweden, Switzerland, the United Kingdom (UK) and the United States (US). Results for the Canadian market are reported at the national level, as well as for the private and public market segments."
|Department/Agency||Patented Medicine Prices Review Board.|
|Title||Cost pressure of the new hepatitis C drugs in Canada|
|Subtitle||Pressions exercées sur les coûts des nouveaux médicaments contre l’hépatite C au Canada.|
|Language||Bilingual-[English | French]|
|Electronic Document|| |
Note: The URLs contained in this/these document(s) may no longer be functional
|Note||Caption title. At head of title: National Prescription Drug Utilization Information System.|
|Number of Pages|| p. :|
|Subject Terms||Hepatitis, Drugs, Prices|
- Date modified: